re: genelabs Select could not have mentioned the Genelabs sale to the shareholders as it was market sensitive.
From my sources, they have been aware, and apart from the delay there is no impact to the concluding of the Hep E deal.
The new company will be more focussed on daignostics and this is a positive.
Should be hearing more on the conclusion of Hep E deal soon, I'd expect.
